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Introduction
Tumor necrosis factor (TNF, originally cachectin or
TNF-a) is the prototype member of a large family of
proteins with diverse functions including induction of
apoptosis and regulation of lymphocyte proliferation.
These ligands bind and signal through members of the
TNF-receptor (TNFR) family of cell-surface receptors
(Bazzoni and Beutler 1996). TNF itself can exhibit an
extraordinarily broad spectrum of biological effects. In
T cell–dependent immune responses, for example, TNF
can, in principal, play critical roles in the induction,
perpetuation, and resolution of the host response (fig.
1). It is not surprising, therefore, that, when TNF is
absent or its activity is blocked, wide-ranging physio-
logical and immunologic processes fail. These range
from increased susceptibility to intracellular bacterial in-
fection to the loss of normal lymphoid tissue micro-
architecture.
Dysregulation and, in particular, overproduction of
TNF has been implicated in a variety of human diseases
including sepsis, cerebral malaria, and autoimmune dis-
eases such as multiple sclerosis, rheumatoid arthritis
(RA), systemic lupus erythematosus, and Crohn disease,
as well as cancer (reviewed in Zhang and Tracey 1998).
Susceptibility to many of these diseases is thought to
have a genetic basis, and the TNF gene is considered a
candidate-predisposing gene. However, unraveling the
importance of genetic variation in the TNF locus to dis-
ease susceptibility or severity is complicated by its lo-
cation within the major histocompatibility complex
(MHC), a highly polymorphic region that encodes nu-
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merous genes involved in immunologic responses (re-
viewed in Gruen and Weissman 1997). In this report,
we review studies that analyze the contribution of TNF
and related genes to susceptibility to human disease. Fur-
thermore, we discuss how the presence of the TNF locus
within the MHC may potentially complicate the inter-
pretation of studies in animal models in which the TNF
locus is experimentally manipulated.
Genomic Localization and Molecular Forms of TNF
and Related Molecules
The human MHC gene cluster, localized on chro-
mosome 6 (chromosome 17 in the mouse), is divided
into four regions (fig. 2). Class I HLA genes are found
at the telomeric end of the cluster, with class II genes at
the centromeric end. Two other extended loci are the
class III region, which encodes several components of
the complement system, and the more recently demar-
cated class IV region. The TNF gene, along with two
related genes, encoding lymphotoxin-a (LTa, previously
known as TNFb) and LTb (Gruen and Weissman 1997),
occur within the MHC class IV cluster.
TNF can be produced by a wide variety of cells, but
the activated macrophage constitutes the most abundant
source of this factor (Vassalli 1992). TNF is first pro-
duced as a cell-membrane–bound, 26-kD molecule that
is cleaved from the cell surface by a metalloproteinase
disintegrin TACE (TNF-a converting enzyme) to gen-
erate a secreted 17-kD form of the TNF molecule (fig.
3). Membrane as well as secreted forms of TNF trimerize
and interact as homotrimers with two TNF recep-
tors—TNF-R1 (human p60, mouse p55) and TNF-R2
(human p80, mouse p75). Both receptors are initially
integral membrane proteins but can be cleaved from the
cell surface, to become bioactive soluble molecules (re-
viewed in Bazzoni and Beutler 1996).
LTa expression is much more restricted than that of
TNF and is predominantly, if not exclusively, found in
T lymphocytes, B cells, and NK cells (Beutler 1992). LTa
is distinct from TNF in having no transmembrane re-
gion, although, like TNF, it can form a soluble homo-
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Figure 1 TNF actions in inflammation from genesis to resolution. TNF may contribute to each step of inflammation by any of the
following mechanisms. Step 1, Organization of secondary lymphoid organs and dendritic cell maturation. Steps 2 and 3, Regulation of adhesion
molecule expression. Step 4, Up-regulation of MHC expression in synergy with other cytokines. Step 5, Induction of leukocyte activation and
adhesion. Step 6, Chemoattractant production by endothelial cells, facilitating leukocyte transmigration. Step 7, Rearrangement of endothelial
cell cytoskeleton, causing vascular leakage. Step 8, Induction of chemokine secretion by stromal cells and inflammatory leukocytes; protease
release by leukocytes. Step 9, Direct cytotoxicity, induction of secondary inflammatory mediators and cytotoxic molecules. Step 10, Induction
of down-regulatory molecules, direct effect of T cell apoptosis. APC  antigen-presenting cell.
trimer (LTa3) that interacts with the same two TNF
receptors (fig. 3; Bazzoni and Beutler 1996). The phys-
iological significance of this interaction, at least in mice,
has been questioned (Mackay et al. 1997), although
there is evidence that interactions between LTa3 and
TNF-R1 may promote formation of lymphoid aggre-
gates in regions of chronic inflammation (Sacca et al.
1998). LTa forms a heterotrimer with LTb—an integral
membrane protein that acts as a membrane anchor—to
generate LTa1b2 (see fig. 3), which interacts with a dis-
tinct receptor, the LTb receptor (LTbR, Bazzoni and Beu-
tler 1996). Because LTb is expressed more widely than
LTa, the formation of this heterotrimer may be con-
trolled by the rate-limiting production of LTa.
Polymorphisms in the TNF Locus: Implications for
Production and Consequences for Disease
A number of MHC class I and class II alleles have
been positively identified as predisposing to various dis-
eases, most of them autoimmune in nature (Theofilo-
poulos 1995). However, in other cases, initial low-res-
olution mapping of disease susceptibility to the MHC
region has, upon closer examination, been shown to be
independent of class I and class II genes. Other candidate
genes that encode proteins involved in inflammation,
stress responses, or host defense are located in the closely
linked MHC class III and class IV region (Gruen and
Weissman 1997). A number of studies have focused on
the TNF locus as one of these candidates.
In rodents there is evidence that polymorphisms in an
AU-rich element within the 3′ untranslated region of the
TNF mRNA may underlie differences in inducible TNF
production across a range of inbred mouse strains. To
test this possibility, Kollias’s group prepared gene-tar-
geted mice that lack this element, and they found that
TNF mRNA is abnormally stable in these animals and
that the protein is produced by cells such as synovial
fibroblasts, wherein TNF production is normally re-
pressed. Mice with this mutation spontaneously devel-
oped an erosive arthritis (Kontoyiannis et al. 1999).
In humans, the significance of polymorphisms in TNF
is much less clear. Healthy individuals exhibit a consid-
erable variation in their levels of mitogen-induced TNF
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Figure 3 The interaction of TNF and LT proteins with their
receptors. Receptors recognize trimeric forms of the TNF and LT li-
gands. There is speculation regarding the extent of oligomerization of
receptors upon ligand binding (Bazzoni and Beutler 1996). s  se-
creted; m  membrane-associated.
Figure 2 The human MHC region and the TNF-related genes. In this physical map of the MHC region, classic HLA class I and class II
genes are depicted in green. The MHC class IV region is shown in greater detail on the middle line. In addition to TNF, LTa, and LTb, class
IV genes with possible functions in immunologic responses include SK12W (antiviral activity), heat shock protein 70 (Hsp70, putative role in
autoimmune inflammation), allograft inflammatory factor-1 (AIF-1, allograft rejection), 1C7 (member of the Ig superfamily, expressed by
monocytes, putative role in macrophage activation), B144 (or leukocyte-specific transcript-1, LST-1, involved in macrophage activation), IkB-
like (IkBL, negative regulation of NFkB), HLA-B–associated transcript-1 (BAT1, RNA helicase involved in B144 splicing) and MHC class
I–related genes A and B (MIC-A and MIC-B, heat-shock induced) (Gruen and Weissman 1997). The bottom line shows the genomic organization
of the LTb, TNF, and LTa genes. Open boxes represent exons. Arrows indicate transcriptional direction. Polymorphisms involving GrA
transitions at positions 376, 308, 244, 238, and 163, and a C insertion at position 70 of TNF are shown.
production. TNF responses have been associated with
certain HLA alleles: HLA-DR3 and -DR4 correlate with
the “high-producing” phenotype for TNF, whereas
HLA-DR2 occurs with the “low-producing” phenotype
(Jacob et al. 1990). An alternative explanation for the
association with class II alleles is that the differences
reflect polymorphisms in closely linked gene(s), includ-
ing the TNF gene itself. To date, nine polymorphisms
and five microsatellites in the TNF locus have been char-
acterized. Six of these polymorphisms are located in the
TNF promotor region (fig. 2), and might, therefore, in-
fluence the transcription rate of this gene. Indeed, as
reviewed in Wilson et al. (1995), TNF synthesis levels
in peripheral blood may correlate with some of these
polymorphisms. One well-studied polymorphism, which
carries a GrA transition at position 308, is strongly
associated with the high-producer HLA-DR3 allele and
is implicated in the risk of death from cerebral malaria
(Zhang and Tracey 1998). Wilson et al. (1997) raised
considerable interest with their report that the 308A
allele is transcribed in vitro at seven times the rate of
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the 308G allele, but this result has not been confirmed
(Brinkman et al. 1996). Stuber et al. (1996) showed that
the 308A allele does not affect the outcome of sepsis,
as might have been supposed, given that high TNF pro-
duction during sepsis confers a high risk of fatal shock.
A complicating factor in the search for disease-asso-
ciated genes in the human population is that many dis-
eases studied are very heterogeneous clinically and that
certain genetic factors may not associate with the ab-
sence or presence of a disease but with its severity or
course. For example, TNF polymorphisms have been
shown to correlate to clinical outcome of RA (Brinkman
et al. 1997). In a large group of RA patients, the TNF
238GA genotype was associated with the absence
of erosive disease compared with the more typical
238GG genotype. Because similar frequencies of the
TNF238GA genotype are observed in RA patients and
healthy controls, the effect of this polymorphism appears
to be limited to disease modification, rather than to pre-
disposition. Despite extensive research efforts, no human
TNF allelic forms have been identified that result in sub-
stantial alterations in TNF expression or regulation, and
no definitive disease-related TNF polymorphism has
been characterized.
Even if a strong correlation between TNF levels and
disease susceptibility or severity can be demonstrated, it
would not necessarily follow that the defect lies in the
TNF gene itself. Any gene involved in regulating the
expression or activity of TNF may be the culprit. For
example, soluble TNF receptors provide a further level
of regulation, controlling the availability of bioactive
TNF levels by binding and neutralizing secreted or
membrane-bound TNF. Indeed, in mice deficient in TNF-
R1 or TNF-R2, levels of inducible TNF are elevated
substantially (Peschon et al. 1998). Possibly related to
this effect is a recent study showing that mutations in
the extracellular domain of human TNF-R1 are linked
to dominantly inherited autoinflammatory syndromes
(McDermott et al. 1999). These TNF-R1 mutations lead
to decreased receptor shedding and a consequent in-
crease in cell-surface expression of TNF-R1. How this
produced the clinical syndromes remains unclear, but
they may have occurred because (1) mutations in TNF-
R1 result in increased levels of circulating TNF or (2)
an increase in the stability of membrane-bound receptor
results in some form of excessive overstimulation.
Animal Models for Human Disease: The Application
and Limitations of Gene Targeting
The close genetic linkage between the TNF locus and
other molecules within the MHC, many of which are
plausible candidate genes in immunologic disorders, un-
doubtedly complicates the study of these human dis-
eases. Less widely appreciated is the fact that the synteny
of these genes is conserved in other model organisms,
and there exists a similar challenge to analyses of these
disease processes in genetically engineered mice. Inbred
mouse strains differ substantially and reproducibly in
their responses to different kinds of pathogens or anti-
gens, and the relevance of HLA class I and class II genes
to these phenotypes is a matter of considerable interest.
Gene targeting, which allows both knock-out and
knock-in genotypes to be constructed, would appear to
provide a useful tool to distinguish the effects of these
polymorphisms from those that occur in TNF or other
MHC class IV genes. However, gene targeting is usually
performed using embryonic stem (ES) cells derived from
the 129 mouse strain (Galli-Taliadoros et al. 1995), and
the targeted mutation is routinely introduced into the
genetic background of interest by means of multiple
rounds of backcrossing. In common practice, experi-
ments of this kind are generally reported after relatively
few rounds of backcrossing, so there is often a consid-
erable contribution of the 129 strain to the genotypes
of the animals studied (Gerlai 1996). Moreover, with
respect to mutations introduced into genes within the
MHC, such as TNF and LTa, even if the standard 12
generations of backcrossing are performed (so that the
animals with the targeted allele carry !0.5% of the 129
genotype), the mutation of interest will still most likely
exist on an MHC background characteristic of the 129
strain. The small genetic distances within the MHC clus-
ter introduce linkage disequilibrium among these genes.
Worse still is the (usually sound) practice of using non-
targeted littermates as controls in these experiments. Be-
cause of linkage disequilibrium, the targeted mutation
will not be the only difference between the experimental
and the control group.
The most satisfactory solution to this problem is to
create targeted mutations in ES cells derived from the
exact strain in which studies are to be performed. In this
way, all backcrossing can be avoided. In our studies of
experimental autoimmune encephalomyelitis (EAE)—an
animal model for the human disease multiple sclero-
sis—we used ES cells derived from the C57BL/6 mouse
strain to generateTNF/, LTa/, andTNF/LTa/mice
(Ko¨rner et al. 1997a; Riminton et al. 1998). This pa-
rental strain is susceptible to a form of EAE that is in-
duced by injecting a fragment of the myelin oligoden-
drocyte glycoprotein (MOG), a minor component of
CNS myelin.
TNF in Inflammatory Autoimmune Disease
In wild-type (WT) C57BL/6 mice, immunization with
MOG leads to the development of clinical deficits, rang-
ing from mild paralysis of the hind limbs to full quad-
riplegia. Clinical signs typically develop within 10–12
days after immunization, reaching a peak of severity by
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day ∼17. The disease remains at this high level for ∼20
days and then resolves to a mild deficit by day ∼40.
TNF/ mice develop clinical disease 5–7 days later than
WT mice but then develop a severe clinical episode by
day 20, with recovery at the same time as WT mice,
despite the later onset (Ko¨rner et al. 1997b). Within the
CNS of both WT and TNF/ mice, a comparable level
of demyelination occurs. Thus, even in the absence of
TNF, clinical signs of EAE can develop, resolution of
the disease appears normally, and demyelination pro-
ceeds. To understand the delayed onset of disease, we
examined the CNS immunohistochemically and ana-
lyzed the population of inflammatory leukocytes in the
CNS of both WT and TNF/ mice at early stages after
MOG inoculation. In WT animals at day 10–12, CNS
perivascular inflammatory lesions are present, whereas
the CNS ofTNF/ mice appeared uninflamed. However,
leukocytes isolated from the whole CNS tissue are pre-
sent in comparable numbers in both types of mice. Thus,
substantial numbers of leukocytes accumulate in the
TNF/CNS but fail to form infiltrates within the CNS
parenchyma. Precisely where these cells are distributed
has not been defined, but localization to the perivascular
space of capillaries and the meningeal vessels is likely.
By day 20, when TNF/ mice exhibit clinical signs of
EAE, visible perivascular accumulations form. However,
here also, leukocyte positioning is distinctive of WT
mice, with cells forming tight aggregates around the mi-
crovasculature and with a remarkable lack of infiltration
of the CNS parenchyma in the absence of TNF. Thus,
throughout the immunologic process necessary for au-
toimmune inflammation in the CNS (see fig. 1), the only
stage that is shown to be solely dependent on TNF is
leukocyte movement within the tissue parenchyma. This
is not to say that TNF cannot play a role in other steps
of the inflammatory process; rather, TNF is not essential
for those processes.
The conclusion from our EAE studies regarding a cen-
tral role for TNF in leukocyte movement is strengthened
by studies in TNF/ mice, of pulmonary infection with
Mycobacterium tuberculosis (Bean et al. 1999), NK cell
localization within the peritoneum (Smyth et al. 1998),
and lymphoid tissue integrity (Pasparakis et al. 1996;
Ko¨rner et al. 1997a). In all cases, as in our work with
the CNS, leukocytes fail to localize normally within in-
flamed tissues in the absence of TNF. This failure has
significant consequences in each case. Although all leu-
kocyte populations typically associated with the M. tu-
berculosis–infected lung are present in the TNF/ lung,
granulomas, which are necessary to remove bacilli, fail
to form with their normal structure, and these mice show
a greatly increased susceptibility to infection. NK cell
development appears equivalent in WT and TNF/
mice, and NK cells from the latter kill MHC class I
negative tumors efficiently in vitro. Thus, TNF is not an
essential cytotoxic effector molecule for NK cells, but,
when the same tumors are instilled in the peritoneum of
TNF/ mice, the failure of NK cell localization permits
tumor growth at that site. Finally, although all leukocyte
populations in the spleen, lymph nodes, and Peyer’s
patches of TNF/ mice are comparable in number and
ratio to those of the WT, primary B cell follicles fail to
form and follicular dendritic cells are not localized nor-
mally within the existing B cell area. The normal T cell–B
cell regional demarcations are completely absent in
Peyer’s patches or lack precise definition in lymph node
and spleen.
A prime candidate for the mediator of TNF-induced
leukocyte trafficking is the chemokine family (also see
Broide et al. 1999 [in this issue]). Chemokines control
cellular interactions and movement in a precise and often
cell-specific fashion and probably are important in all
tissues and for the localization of many cell types, not
only those of hematopoietic derivation. A simple expla-
nation is that chemokine induction at a broad level re-
quires TNF. Indeed, a role for TNF in induction or up-
regulation of leukocyte chemoattractants has been rec-
ognized for a decade, and the list of TNF-inducible che-
mokines is growing (Tessier et al. 1997). In the spleen,
steady-state mRNA levels of a range of lymphocyte hom-
ing chemokines are reduced significantly in mice lacking
TNF or TNF-R1 (Ngo et al. 1999). Furthermore, there
is now abundant evidence that inflammation of the CNS
is dependent on the induction of certain chemokines
(Karpus and Ransohoff 1998), although it is not yet clear
whether loss of TNF is sufficient to abolish the produc-
tion of chemoattractants in CNS inflammation. Analyses
similar to those conducted in the spleen (Ngo et al. 1999)
must now be performed by means of inflamed CNS tis-
sues from TNF/ and WT mice. The evidence is far
more direct in lung inflammation, in which production
of the leukocyte chemoattractants MCP-1, MIP-2, and
MIP-1a within the lung is compromised after treatment
with anti-TNF antibody (Czermak et al. 1999).
TNF and LT Function in Autoimmune Inflammation:
Inconsistencies and Controversies
The numerous studies, both clinical and experimental,
showing inhibition of disease processes after TNF-block-
ing therapies argue for a significant role for TNF in
promoting inflammation (reviewed in Feldmann et al.
1998). The mode of TNF action we have identified from
studies in TNF gene-targeted mice is likely to be a pre-
eminent one targeted by anti-TNF therapies. Conversely,
there is evidence that TNF may contribute to resolution
of inflammation (Cope 1998), but the mechanisms re-
sponsible for the effect and the range of circumstances
in which it occurs remain undefined. However, it is dis-
turbing to note the contrasting outcomes of EAE studies
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in TNF/ mice, including those that indicate a role for
TNF in disease onset and acceleration (Ko¨rner et al.
1997b), or in disease inhibition (Liu et al. 1998), or that
conclude, by inference from studies in LTa mice, that
TNF has no role at all (Suen et al. 1997). These incon-
sistencies may be explained, at least in some cases, by
inappropriate comparisons of mutated and WT mice, in
which the differences between the two groups exceed the
single mutation that is the object of the study. Thus, in
one study, Kassiotis et al. (1999) introduced the
TNF/ mutation from 129 mice, which carry the H-2b
haplotype, onto the EAE-susceptible SJL/J (H-2s) mouse
strain, thereby effectively changing the MHC haplotype
of the SJL/J mouse from s to b. To circumvent the dif-
ficulties caused by linkage between TNF and the other
MHC genes, these authors used SJL/J-H-2b congenic
mice as controls. After eliciting EAE by inoculating the
animals with a CNS autoantigen to which SJL/J mice
are susceptible, the authors found that TNF/ mice
show delayed disease onset and that inflammatory cuff-
ing was more restricted to the immediate perivascular
space (also see Ko¨rner et al. 1997b). Thus, when mutated
and control mice are appropriately matched, TNF ap-
pears to be a consistent and significant factor in leu-
kocyte motility during autoimmune inflammation.
Despite the difficulty of extracting clear answers about
the role of TNF in these diseases, it may prove more
challenging still to address the corresponding questions
about the LTa and LTb genes. These genes are also
tightly linked to other MHC loci, but, unlike TNF, they
are also clearly implicated in lymphoid tissue neogenesis.
Mice in which LTa1b2 -LTbR interactions are prevented
by gene-targeting of ligand or receptor or by injecting
specific inhibitors (Fu and Chaplin 1999) have neither
lymph nodes nor Peyer’s patches, and their splenic mi-
croarchitecture is substantially disturbed. In the spleen
of these mice, as in TNF/ mice, structural disorgani-
zation is associated with a reduction in expression of T
and B cell homing chemokines (Ngo et al. 1999). Con-
sistent with the extent of the phenotype, absence of LT
signaling results in a more drastic loss of chemokine
expression in the spleen than is seen in TNF/ mice.
Data on the autoimmune responses of these mutant
animals are inconsistent and difficult to interpret. In one
study (Suen et al. 1997), LTa/ mice, which exhibit
lymphoid tissue abnormalities, appeared poorly suscep-
tible to EAE, relative to structurally normal, LTa-ex-
pressing WT mice. In another study of mice lacking both
LTa and TNF, with one immunization regimen, the de-
ficient mice were more severely affected than were the
control, TNF/LTa–positive mice (Frei et al. 1997). Dis-
sociating the consequences of functional LT absence
(namely, the loss of lymphoid tissues) from a direct role
of LT as an effector of the inflammatory process is dif-
ficult. Our own analyses indicate that, where structure
is corrected but LT deficiency remains, mice become as
susceptible to EAE as WT control mice (Riminton et al.
1998). Thus, controversy remains.
Therapeutic Opportunities and Experimental
Challenges Ahead
The mechanism(s) by which in vivo TNF blockade
induces a clear therapeutic benefit, particularly in RA
and Crohn disease, remain(s) undefined (Feldmann et al.
1998; Hodgson 1999). Nevertheless, the success of this
therapeutic modality indicates in an unequivocal way in
humans, as opposed to animal model systems, the im-
portance of TNF at key point(s) in inflammation and
tissue damage. Whether diseases of this type reflect ab-
normalities/dysfunction specifically of the TNF gene or
rather a necessary role for TNF in some other dysre-
gulated pathway of inflammation requires further study.
The outcome of animal model experiments discussed
here indicate that the generation of chemokine gradients
in tissues can be a TNF-dependent process and that sub-
verting this probably contributes to the success of TNF-
directed therapies. Hence, should future analysis of hu-
man inflammatory disease–susceptibility genes point to
a genomic region that would include the TNF locus,
associated evidence of dysregulated chemokine expres-
sion or disturbances in leukocyte movement may be a
useful surrogate marker pinpointing specific effects to
the TNF gene.
Separating the contributions of secreted LTa3 and
TNF in inflammation remains problematic. Not only are
the TNF and LT genes closely linked and not only may
the loss of LT activities introduce confounding effects
on lymphoid tissue integrity, but some effective thera-
peutics, such as TNFR-Ig fusion proteins, are capable
of binding both proteins. Conversely, specific mono-
clonal antibodies neutralizing TNF but not LT are also
highly effective in the treatment of RA and Crohn disease
(Feldmann et al. 1998). The implication is that inhibiting
TNF alone is sufficient. Whether there proves to be some
advantage (or disadvantage) in additional neutralization
of LT activity awaits further experience with TNF-spe-
cific vs TNF/LTa–blocking agents.
Finally, the relative importance of the membrane ver-
sus secreted forms of TNF in inflammation and tissue
damage is an important issue, particularly given the view
that drugs such as the TACE inhibitors, which prevent
TNF cleavage from the cell surface, may be useful anti-
inflammatories. That there could be no therapeutic effect
or, worse, adverse consequences because of an increased
concentration of biologically active TNF at the cell sur-
face has not been fully appreciated or studied in any
depth. At least two groups, our own included, have re-
cently developed gene knock-in mice that express only
a noncleavable form of TNF. The ability of membrane-
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associated TNF alone to mediate the range of biologi-
cal functions most commonly attributed to the secreted
form of TNF should soon be documented in an in vivo
system.
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